Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Joel Gallant

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Living Beings

HIV-1
HIV

Physiology

Viral Drug Resistance

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Gallant Joel E; Moore Richard D
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Gallant Joel E
CROI 2009: a few key presentations on antiretroviral therapy.
Gallant Joel E
Preaching to the choir: advocating routine HIV testing.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Joel Gallant (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Gallant Joel E; Moore Richard D
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
AIDS (London, England) 2009;23(15):1971-5.
2009: Gallant Joel E
CROI 2009: a few key presentations on antiretroviral therapy.
The AIDS reader 2009;19(4):129-30, C3.
2009: Gallant Joel E
Preaching to the choir: advocating routine HIV testing.
The AIDS reader 2009;19(3):89-90.
2009: Gallant Joel
HIV drug guide introduction. A brief description of the drug classes and how they work.
Positively aware : the monthly journal of the Test Positive Aware Network 2009;20(2):24-5.
2009: Apuzzo Linda G; Vaida Florin; Gallant Joel E; Ernstrom Karin B; Little Susan J; Routy Jean-Pierre; Collier Ann C; Conway Brian; Markowitz Martin H; Hecht Frederick M; Walker Bruce D; Connick Elizabeth; Margolick Joseph B
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2009;50(3):267-75.
2009: Grant Philip; Taylor Jonathan; Cain Pat; Short William; Gallant Joel; Farthing Charles; Thal Gary; Coakley Eoin; Zolopa Andrew
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(5):680-2.
2009: Gallant Joel E
When to start antiretroviral therapy? NA-ACCORD stimulates the debate.
The AIDS reader 2009;19(2):49-50, 61.
2009: Wilson Lucy E; Gallant Joel E
HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(2):214-21.
2008: Gallant Joel E; Winston Jonathan A; DeJesus Edwin; Pozniak Anton L; Chen Shan-Shan; Cheng Andrew K; Enejosa Jeffrey V
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
AIDS (London, England) 2008;22(16):2155-63.
2008: Nachega Jean B; Hislop Michael; Dowdy David W; Gallant Joel E; Chaisson Richard E; Regensberg Leon; Maartens Gary
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
AIDS (London, England) 2008;22(16):2117-25.
2008: Gallant Joel
Wellness checklist. Important things to consider when you're HIV-positive.
Positively aware : the monthly journal of the Test Positive Aware Network 2008;19(5):36-7.
2008: Gallant Joel E; Arribas José R
Antiretroviral rounds. Is that "one pill" treatment enough?
AIDS clinical care 2008;20(7):53-4.
2008: Hoffmann Christopher J; Gallant Joel E
Initial regimens for the treatment-naive patient: current understanding and practice.
The AIDS reader 2008;18(6):326-30, 336-8.
2008: Gallant Joel E
When to start antiretroviral therapy: a swinging pendulum?
Topics in HIV medicine : a publication of the International AIDS Society, USA 2008;16(2):82-8.
2008: Solomon S S; Hawcroft C S; Narasimhan P; Subbaraman R; Srikrishnan A K; Cecelia A J; Suresh Kumar M; Solomon Suniti; Gallant J E; Celentano D D
Comorbidities among HIV-infected injection drug users in Chennai, India.
The Indian journal of medical research 2008;127(5):447-52.
2008: Han Yefei; Lai Jun; Barditch-Crovo Patricia; Gallant Joel E; Williams Thomas M; Siliciano Robert F; Blankson Joel N
The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors.
AIDS (London, England) 2008;22(4):541-4.
2008: Diaz-Linares Mariela; Vázquez Enid; Gallant Joel; Delaney Martin
12th annual HIV drug guide.
Positively aware : the monthly journal of the Test Positive Aware Network 2008;19(1):19-48.
2008: Gallant Joel
HIV drug guide introduction. A brief description of the drug classes and how they work.
Positively aware : the monthly journal of the Test Positive Aware Network 2008;19(1):18.
2008: Gallant Joel
Antiretroviral therapy update. Everything you need to know, in a nutshell.
Positively aware : the monthly journal of the Test Positive Aware Network 2008;19(1):10-3.
2008: Arribas Jose R; Pozniak Anton L; Gallant Joel E; Dejesus Edwin; Gazzard Brian; Campo Rafael E; Chen Shan-Shan; McColl Damian; Holmes Charles B; Enejosa Jeffrey; Toole John J; Cheng Andrew K
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2008;47(1):74-8.
2007: Gallant Joel E
Making sense of blips.
The Journal of infectious diseases 2007;196(12):1729-31.
2007: Gallant Joel E
Should antiretroviral therapy be started earlier?
Current HIV/AIDS reports 2007;4(2):53-9.
2007: Hoffman Christopher J; Gallant Joel E
When and how to use tipranavir and darunavir.
The AIDS reader 2007;17(4):194-8, 201.
2007: Gallant Joel E
Report from Los Angeles: the 14th Conference on Retroviruses and Opportunistic Infections (CROI). Management of treatment-naïve patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2007;19(2):1-3, 12.
2007: Gallant Joel E
Approach to the treatment-experienced patient.
Infectious disease clinics of North America 2007;21(1):85-102, viii-ix.
2007: Haubrich Richard; Berger Dan; Chiliade Philippe; Colson Amy; Conant Marcus; Gallant Joel; Wilkin Timothy; Nadler Jeffrey; Pierone Gerald; Saag Michael; van Baelen Ben; Lefebvre Eric;
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
AIDS (London, England) 2007;21(6):F11-8.
2007: Siliciano Janet D; Lai Jun; Callender Marc; Pitt Eleanor; Zhang Hao; Margolick Joseph B; Gallant Joel E; Cofrancesco Joseph; Moore Richard D; Gange Stephen J; Siliciano Robert F
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
The Journal of infectious diseases 2007;195(6):833-6.
2007: Sax Paul E; Gallant Joel E; Klotman Paul E
Renal safety of tenofovir disoproxil fumarate.
The AIDS reader 2007;17(2):90-2, 99-104, C3.
2007: Gallant Joel E
Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(3):453-5.
2007: Gallant Joel E
Antiretroviral update from the 46th ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2007;19(1):1-3, 12.
2007: Riddell James; Kaul Daniel R; Karakousis Petros C; Gallant Joel E; Mitty Jennifer; Kazanjian Powel H
Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes.
Journal of translational medicine 2007;5():50.
2006: Pozniak Anton L; Gallant Joel E; DeJesus Edwin; Arribas Jose R; Gazzard Brian; Campo Rafael E; Chen Shan-Shan; McColl Damian; Enejosa Jeffrey; Toole John J; Cheng Andrew K
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2006;43(5):535-40.
2006: Gallant Joel E
The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
The AIDS reader 2006;16(10):556-9.
2006: Atta Mohamed G; Gallant Joel E; Rahman M Hafizur; Nagajothi Nagapradeep; Racusen Lorraine C; Scheel Paul J; Fine Derek M
Antiretroviral therapy in the treatment of HIV-associated nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(10):2809-13.
2006: Li Xiuhong; Chu Haitao; Gallant Joel E; Hoover Donald R; Mack Wendy J; Chmiel Joan S; Muñoz Alvaro
Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.
Journal of epidemiology and community health 2006;60(9):811-8.
2006: Gallant Joel E
Editorial comment: predictors of response--updating the traditional list.
The AIDS reader 2006;16(8):432-3.
2006: Estrella Michelle; Fine Derek M; Gallant Joel E; Rahman M Hafizur; Nagajothi Nagapradeep; Racusen Lorraine C; Scheel Paul J; Atta Mohamed G
HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(3):377-80.
2006: Bailey Justin R; Sedaghat Ahmad R; Kieffer Tara; Brennan Timothy; Lee Patricia K; Wind-Rotolo Megan; Haggerty Christine M; Kamireddi Ashrit R; Liu Yi; Lee Jessica; Persaud Deborah; Gallant Joel E; Cofrancesco Joseph; Quinn Thomas C; Wilke Claus O; Ray Stuart C; Siliciano Janet D; Nettles Richard E; Siliciano Robert F
Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.
Journal of virology 2006;80(13):6441-57.
2006: Pham Paul A; Gallant Joel E
Tenofovir disoproxil fumarate for the treatment of HIV infection.
Expert opinion on drug metabolism & toxicology 2006;2(3):459-69.
2006: Gallant Joel E
Editorial comment: treating the experienced patient--when and how to use new agents.
The AIDS reader 2006;16(5):274-5.
2006: Sabundayo Beulah P; McArthur Julie H; Langan Susan J; Gallant Joel E; Margolick Joseph B
High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
Pharmacotherapy 2006;26(5):674-81.
2006: Nettles Richard E; Kieffer Tara L; Parsons Teresa; Johnson James; Cofrancesco Joseph; Gallant Joel E; Carson Kathryn A; Siliciano Robert F; Flexner Charles
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(8):1189-96.
2006: Mbulaiteye Sam M; Atkinson Jonnae O; Whitby Denise; Wohl David A; Gallant Joel E; Royal Scott; Goedert James J; Rabkin Charles S
Risk factors for human herpesvirus 8 seropositivity in the AIDS Cancer Cohort Study.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2006;35(4):442-9.
2006: Gallant Joel E
Antiretroviral news from the 10th EACS, Dublin.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2006;18(1):5-7.
2006: Gallant Joel E
Antiretroviral news from the 45th ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2006;18(1):1-4.
2006: Gallant Joel E; DeJesus Edwin; Arribas José R; Pozniak Anton L; Gazzard Brian; Campo Rafael E; Lu Biao; McColl Damian; Chuck Steven; Enejosa Jeffrey; Toole John J; Cheng Andrew K;
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
The New England journal of medicine 2006;354(3):251-60.
2005: Gallant Joel E
Antiretroviral drug resistance and resistance testing.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2005;13(5):138-42.
2005: Gallant Joel E; Rodriguez Allan E; Weinberg Winkler G; Young Benjamin; Berger Daniel S; Lim Michael L; Liao Qiming; Ross Lisa; Johnson Judy; Shaefer Mark S;
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
The Journal of infectious diseases 2005;192(11):1921-30.
2005: Gallant Joel E
False positive viral load results: recent problems and solutions.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2005;17(6):1, 4.
2005: Nettles Richard E; Keiffer Tara L; Cofrancesco Joseph; Gallant Joel E; Quinn Thomas; Jackson Brooks; Flexner Charles; Carson Kathryn A; Wu Albert W; Siliciano Robert F
Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAART.
HIV clinical trials 2005;6(5):262-71.
2005: Gallant Joel E
3rd IAS conference: initial therapy, switching, and new strategies.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2005;17(5):1-3, 12.
2005: Gallant Joel E; Shafer Robert
Antiretroviral rounds. Virologic failure: true or false?
AIDS clinical care 2005;17(9):84-5.
2005: Gallant Joel E
Approach to the treatment-experienced patient.
Current HIV/AIDS reports 2005;2(2):83-9.
2005: Nawar Eric; Mbulaiteye Sam M; Gallant Joel E; Wohl David A; Ardini Marianne; Hendershot Tabitha; Goedert James J; Rabkin Charles S;
Risk factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS.
International journal of cancer. Journal international du cancer 2005;115(2):296-300.
2005: Gallant Joel E; Parish Michelle A; Keruly Jeanne C; Moore Richard D
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(8):1194-8.
2005: Izzedine Hassane; Hulot Jean Sebastien; Vittecoq Daniel; Gallant Joel E; Staszewski Schlomo; Launay-Vacher Vincent; Cheng Andrew; Deray Gilbert;
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2005;20(4):743-6.
2005: Gallant Joel E
Treatment of naïve patients: update from the 12th CROI.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2005;17(2):4-5.
2005: Nettles Richard E; Kieffer Tara L; Kwon Patty; Monie Daphne; Han Yefei; Parsons Teresa; Cofrancesco Joseph; Gallant Joel E; Quinn Thomas C; Jackson Brooks; Flexner Charles; Carson Kathryn; Ray Stuart; Persaud Deborah; Siliciano Robert F
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
JAMA : the journal of the American Medical Association 2005;293(7):817-29.
2005: Gallant Joel E
Antiretroviral therapy update from the 44th ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2005;17(1):1-3, 7.
2004: Tarwater Patrick M; Gallant Joel E; Mellors John W; Gore Mary E; Phair John P; Detels Roger; Margolick Joseph B; Muñoz Alvaro
Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
AIDS (London, England) 2004;18(18):2419-23.
2004: Gallant Joel E
Editorial comment: strategies for success--a return to "hit early"?
The AIDS reader 2004;14(12):662-3.
2004: Gallant Joel E
XV International AIDS Conference in Bangkok: antiretroviral therapy.
HIV clinical trials 2004;5(6):434-40.
2004: Gallant Joel E
The choice of the nucleoside backbone in initial therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(6):1-6, 10.
2004: Gallant Joel E
Protease-inhibitor boosting in the treatment-experienced patient.
AIDS reviews 2004;6(4):226-33.
2004: Nettles Richard E; Kieffer Tara L; Simmons Rachel P; Cofrancesco Joseph; Moore Richard D; Gallant Joel E; Persaud Deborah; Siliciano Robert F
Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(7):1030-7.
2004: Gallant Joel E
XV International AIDS Conference in Bangkok: antiretroviral therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(5):1-6.
2004: Aberg Judith A; Gallant Joel E; Anderson Jean; Oleske James M; Libman Howard; Currier Judith S; Stone Valerie E; Kaplan Jonathan E;
Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(5):609-29.
2004: Gallant Joel E
The ideal nucleoside/nucleotide backbone.
Journal of acquired immune deficiency syndromes (1999) 2004;37 Suppl 1():S44-51.
2004: Gallant Joel E
Current perspectives on the nucleoside/nucleotide components of combination antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2004;37 Suppl 1():S1.
2004: Gebo Kelly A; Gallant Joel E; Keruly Jeanne C; Moore Richard D
Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2004;36(5):1028-33.
2004: Gallant Joel E
HIV infection--how to lower your risk.
American family physician 2004;70(2):307-8.
2004: Gallant Joel E
HIV counseling, testing, and referral.
American family physician 2004;70(2):295-302.
2004: Gallant Joel E; Staszewski Schlomo; Pozniak Anton L; DeJesus Edwin; Suleiman Jamal M A H; Miller Michael D; Coakley Dion F; Lu Biao; Toole John J; Cheng Andrew K;
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA : the journal of the American Medical Association 2004;292(2):191-201.
2004: Lucas Gregory M; Gallant Joel E; Moore Richard D
Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.
AIDS (London, England) 2004;18(11):1539-48.
2004: Gallant Joel E
Editorial comment: thoughts on the once-daily-dosing bandwagon.
The AIDS reader 2004;14(6):330-1.
2004: Sethi Ajay K; Celentano David D; Gange Stephen J; Gallant Joel E; Vlahov David; Farzadegan Homayoon
High-risk behavior and potential transmission of drug-resistant HIV among injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2004;35(5):503-10.
2004: Blankson Joel N; Gallant Joel E
Early treatment of HIV.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(2):14.
2004: Gallant Joel E
Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). Antiretroviral therapy: the naïve patient.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(2):1-4.
2004: Persaud Deborah; Gallant Joel E
Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). The tenacity of NNRTI drug resistance.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(2):1, 5, 15.
2003: Gallant Joel E; Gerondelis Peter Z; Wainberg Mark A; Shulman Nancy S; Haubrich Richard H; St Clair Marty; Lanier Ernest R; Hellmann Nicholas S; Richman Douglas D
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
Antiviral therapy 2003;8(6):489-506.
2003: Tarwater Patrick M; Parish Michelle; Gallant Joel E
Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(11):1541-8.
2003: Gallant Joel E
Antiretroviral news from the Chicago: the 43rd ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(6):1-4.
2003: Gallant Joel E; Pham Paul A
Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
Expert review of anti-infective therapy 2003;1(3):415-22.
2003: Sethi Ajay K; Celentano David D; Gange Stephen J; Moore Richard D; Gallant Joel E
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(8):1112-8.
2003: Gallant Joel E; Deresinski Stanley
Tenofovir disoproxil fumarate.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(7):944-50.
2003: Gallant Joel E
Antiretroviral therapy update from the 2nd IAS Conference.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(5):1-4.
2003: Gallant Joel E
AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(4):1-2.
2003: Gallant Joel E
The optimal use of enfuvirtide.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(3):1-3.
2003: Gallant Joel E
Drug resistance and treatment of experienced patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(2):8-9.
2003: Gallant Joel E
Report from Boston: the 10th Conference on Retroviruses and Opportunistic Infections (CROI).
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(2):1-2, 11.
2003: Kuritzkes Daniel R; Boyle Brian A; Gallant Joel E; Squires Kathleen E; Zolopa Andrew
Current management challenges in HIV: antiretroviral resistance.
The AIDS reader 2003;13(3):133-5, 138-42.
2003: Lalezari Jacob P; Eron Joseph J; Carlson Margrit; Cohen Calvin; DeJesus Edwin; Arduino Roberto C; Gallant Joel E; Volberding Paul; Murphy Robert L; Valentine Fred; Nelson Emily L; Sista Prakash R; Dusek Alex; Kilby J Michael
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
AIDS (London, England) 2003;17(5):691-8.
2003: Jackson J Brooks; Barnett Scott; Piwowar-Manning Estelle; Apuzzo Linda; Raines Charles; Hendrix Craig; Hamzeh Fayez; Gallant Joel
A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk.
AIDS (London, England) 2003;17(4):547-53.
2003: Gallant Joel E
Current status of antiretroviral treatment interruption and intermittent therapy strategies.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(1):8-9, 16.
2003: Gallant Joel
Tipranavir.
Drugs 2003;63(15):1619-20.
2002: Shulman Nancy; Zolopa Andrew; Havlir Diane; Hsu Ann; Renz Cheryl; Boller Sheila; Jiang Ping; Rode Richard; Gallant Joel; Race Elizabeth; Kempf Dale J; Sun Eugene
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.
Antimicrobial agents and chemotherapy 2002;46(12):3907-16.
2002: Gallant Joel E
Initial therapy of HIV infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2002;25(3):317-33.
2002: Gallant Joel E
Report from ICAAC: new drugs and antiretroviral therapy for naïve patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2002;14(6):1-3, 7.
2002: Barreiro Pablo; García-Benayas Teresa; Soriano Vincent; Gallant Joel
Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
AIDS reviews 2002;4(4):233-41.
2002: Gallant Joel E
Current status of antiretroviral treatment interruption and intermittent therapy strategies.
MedGenMed : Medscape general medicine 2002;4(3):19.
2002: Gallant Joel E
Drug resistance and the treatment of experienced patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2002;14(5):1, 5-7, 16.
2002: Chaisson Richard E; Gebo Kelly; Flexner Charles; Gallant Joel E; Lucas Gregory M; Bartlett John G
Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections.
HIV clinical trials 2002;3(4):333-49.
2002: Kilby J Michael; Lalezari Jacob P; Eron Joseph J; Carlson Margrit; Cohen Calvin; Arduino Roberto C; Goodgame Jeffrey C; Gallant Joel E; Volberding Paul; Murphy Robert L; Valentine Fred; Saag Michael S; Nelson Emily L; Sista Prakash R; Dusek Alex
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
AIDS research and human retroviruses 2002;18(10):685-93.
2002: Blankson Joel N; Gallant Joel E; Quinn Thomas C; Bartlett John G; Siliciano Robert F
Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients.
JAMA : the journal of the American Medical Association 2002;288(2):162-4.
2002: Gallant Joel E
New drugs in clinical development and treatment of naive patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2002;14(2):10-1.
2002: Gallant Joel E
Antiretroviral news from the 41st ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2002;14(1):1-5.
2001: Gallant J E
My doc wants me to have another genotype panel. The HMO will not pay for this test. Last time, it cost my lover and me more than $900 from a lab in California. Do you know of some less costly providers of genotype tests? $900 is a lot of money! And do you have any information on when (if ever) the FDA is going to approve these tests, so the insurance companies will pay for them?
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(6):11.
2001: Gallant J E
After a person has built resistance to a drug and then goes on other drugs for a while, is it possible that the virus loses its resistance to the first drug after not being in their system for awhile, or will the virus be resistant to that drug for the rest of his/her life?
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(6):11.
2001: Gallant J E
AIDS freak-time to give up?
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(6):11.
2001: Gallant J E
What is the latest news on structured interrupted treatment? Should a healthy HIV positive person consider an STI? What are the risks involved and for how long should the meds be interrupted? Is there any chance of developing resistance?
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(6):10.
2001: Gallant J E
Report from Buenos Aires on new drugs.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(5):8, 16.
2001: Gallant J E
Report from Buenos Aires: the 1st IAS Conference on HIV Pathogenesis and Treatment.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(5):1-7, 15.
2001: Celentano D D; Galai N; Sethi A K; Shah N G; Strathdee S A; Vlahov D; Gallant J E
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
AIDS (London, England) 2001;15(13):1707-15.
2001: Bartlett J G; Gallant J E
Recommendations for HIV-positive inmates.
Positively aware : the monthly journal of the Test Positive Aware Network 2001;12(4):30-1.
2001: Gallant J E
The Moore News and The Hopkins HIV Report: a time capsule: 1989-2001.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(4):7, 10-1, 15.
2001: Gallant J E
Antiretroviral therapy: naïve patients and early therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(2):3-4, 15.
2001: Gallant J E
New antiretroviral agents.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(2):2, 16.
2001: Lucas G M; Sterling T R; Bartlett J G; Gallant J E
Selected topics from the 38th annual meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana and selected topics from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Ontario, Canada.
HIV clinical trials 2001;2(2):171-82.
2001: Blankson J N; Gallant J E; Siliciano R F
Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution.
The Journal of infectious diseases 2001;183(4):657-61.
2000: Raines C P; Flexner C; Sun E; Heath-Chiozzi M; Lewis R H; Fields C; Deetz C; Apuzzo L; Eshleman S H; Jackson J B; Gallant J E
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
Journal of acquired immune deficiency syndromes (1999) 2000;25(4):322-8.
2000: Gallant J E
Antiretroviral news from ICAAC 2000.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2000;12(5):8-9, 11.
2000: Gallant J E
Antiretroviral therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2000;12(4):2-3, 14-5.
2000: Hellinger J A; Cohen C J; Stein A J; Gallant J E; Gathe J; Keiser P
Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
HIV clinical trials 2000;1(2):25-8.
2000: Haas D W; Arathoon E; Thompson M A; de Jesus Pedro R; Gallant J E; Uip D E; Currier J; Noriega L M; Lewi D S; Uribe P; Benetucci L; Cahn P; Paar D; White A C; Collier A C; Ramirez-Ronda C H; Harvey C; Chung M O; Mehrotra D; Chodakewitz J; Nguyen B Y;
Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.
AIDS (London, England) 2000;14(13):1973-8.
2000: Gallant J E
Antiretroviral therapy in naïve patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2000;12(2):1, 6-7.
2000: Gallant J E
Strategies for long-term success in the treatment of HIV infection.
JAMA : the journal of the American Medical Association 2000;283(10):1329-34.
1999: Powderly W G; Gallant J E; Ghannoum M A; Mayer K H; Navarro E E; Perfect J R
Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy.
AIDS research and human retroviruses 1999;15(18):1619-23.
1999: Gallant J E
Antiretroviral therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(6):1, 4-5, 8-9.
1999: Gallant J E
Therapy for the treatment-experienced patient.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(5):1, 6-7, 14-5.
1999: Gallant J E
Antiretroviral therapy in the treatment-experienced patient.
The AIDS reader 1999;9(4):284-91.
1999: Hall C S; Raines C P; Barnett S H; Moore R D; Gallant J E
Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
AIDS (London, England) 1999;13(10):1207-12.
1999: Finzi D; Blankson J; Siliciano J D; Margolick J B; Chadwick K; Pierson T; Smith K; Lisziewicz J; Lori F; Flexner C; Quinn T C; Chaisson R E; Rosenberg E; Walker B; Gange S; Gallant J; Siliciano R F
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
Nature medicine 1999;5(5):512-7.
1999: Gallant J E
New antiretroviral agents.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(2):3, 12.
1999: Gallant J E
Antiretroviral therapy in the experienced patient.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(2):1, 4, 9, 16.
1999: Gallant J E; Chaisson R E; Keruly J C; Moore R D
Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients.
AIDS (London, England) 1999;13(2):225-9.
1999: Gallant J E
The new drugs and how to use them.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(1):2, 7.
1998: Gallant J E
Antiretroviral therapy: rehashes, leftovers, and a pinch of new data.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1998;10(6):1, 4, 9-11.
1998: Gallant J E; Chaisson R E; Moore R D
The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications.
Chest 1998;114(5):1258-63.
1998: Gallant J E
Antiretroviral news.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1998;10(5):1, 4-7, 11.
1998: Gallant J E
A review of dual protease inhibitor therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1998;10(3):1, 4-5.
1998: Gallant J E; Block D S
Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients.
Journal of the International Association of Physicians in AIDS Care 1998;4(5):32-5.
1998: Gallant J E
When to switch your drug combo.
Positively aware : the monthly journal of the Test Positive Aware Network 1998;9(1):29.
1998: Chaisson R E; Gallant J E; Keruly J C; Moore R D
Impact of opportunistic disease on survival in patients with HIV infection.
AIDS (London, England) 1998;12(1):29-33.
1997: Finzi D; Hermankova M; Pierson T; Carruth L M; Buck C; Chaisson R E; Quinn T C; Chadwick K; Margolick J; Brookmeyer R; Gallant J; Markowitz M; Ho D D; Richman D D; Siliciano R F
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science (New York, N.Y.) 1997;278(5341):1295-300.
1997: Pons V; Greenspan D; Lozada-Nur F; McPhail L; Gallant J E; Tunkel A; Johnson C C; McCarty J; Panzer H; Levenstein M; Barranco A; Green S
Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(6):1204-7.
1997: Erbelding E J; Chaisson R E; Gallant J E; Moore R D
Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease.
Antiviral therapy 1997;2(2):71-7.
1997: Gallant J E
When to start therapy--and what to start with.
Positively aware : the monthly journal of the Test Positive Aware Network 1997;8(1):22-3.
1997: Maenza J R; Merz W G; Romagnoli M J; Keruly J C; Moore R D; Gallant J E
Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(1):28-34.
1996: Cheever L W; Chaisson R E; Gallant J E
Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus.
The Western journal of medicine 1996;165(1-2):67-73.
1996: Gallant J E; Ko A H
Cavitary pulmonary lesions in patients infected with human immunodeficiency virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;22(4):671-82.
1996: Chaisson R E; Keruly J C; McAvinue S; Gallant J E; Moore R D
Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(5):455-9.
1996: Maenza J R; Keruly J C; Moore R D; Chaisson R E; Merz W G; Gallant J E
Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.
The Journal of infectious diseases 1996;173(1):219-25.
1995: Ko A H; Thomas D L; Gallant J E
Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor.
AIDS (London, England) 1995;9(10):1195-7.
1995: Gallant J E; Moore R D; Keruly J; Richman D D; Chaisson R E
Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
The Journal of infectious diseases 1995;172(2):346-52.
1995: Gallant J E; McAvinue S M; Moore R D; Bartlett J G; Stanton D L; Chaisson R E
The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia.
Chest 1995;107(4):1018-23.
1995: Gallant J E
Infectious complications of HIV disease.
Emergency medicine clinics of North America 1995;13(1):73-104.
1994: Jacobson M A; Gallant J; Wang L H; Coakley D; Weller S; Gary D; Squires L; Smiley M L; Blum M R; Feinberg J
Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
Antimicrobial agents and chemotherapy 1994;38(7):1534-40.
1994: Gallant J E; Moore R D; Chaisson R E
Prophylaxis for opportunistic infections in patients with HIV infection.
Annals of internal medicine 1994;120(11):932-44.
1994: Gallant J E; Moore R D; Richman D D; Keruly J; Chaisson R E
Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
Archives of internal medicine 1994;154(5):566-72.
1993: Gallant J E; Eldred L J; Leslie J M; Chaisson R E; Quinn T C
Impact of the 1993 revision of the CDC case definition on the performance of the WHO and PAHO clinical case definitions for AIDS.
AIDS (London, England) 1993;7(10):1396-7.
1993: Chaisson R E; Stanton D L; Gallant J E; Rucker S; Bartlett J G; Moore R D
Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting.
AIDS (London, England) 1993;7(6):857-62.
1992: Gallant J E; Moore R D; Richman D D; Keruly J; Chaisson R E
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
The Journal of infectious diseases 1992;166(6):1223-7.
1992: Gallant J E; Mueller P S; McArthur J C; Chaisson R E
Intramedullary tuberculoma in a patient with HIV infection.
AIDS (London, England) 1992;6(8):889-91.
1992: Gallant J E; Somani J; Chaisson R E; Stanton D; Smith M; Quinn T C
Diagnostic accuracy of three clinical case definitions for advanced HIV disease.
AIDS (London, England) 1992;6(3):295-9.
1991: Szych C M; Rotter S M; Gallant J E
Papules and nodules in a patient with the acquired immunodeficiency syndrome and recurrent cryptococcal meningitis. Bacillary angiomatosis or epithelioid angiomatosis.
Archives of dermatology 1991;127(12):1832-3, 1835-6.
1991: Gallant J E; Hoehn-Saric E; Smith M D
Respiratory insufficiency from dapsone-induced methemoglobinemia.
AIDS (London, England) 1991;5(11):1392-3.
1988: Gallant J E; Enriquez R E; Cohen K L; Hammers L W
Pneumocystis carinii thyroiditis.
The American journal of medicine 1988;84(2):303-6.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Joel Gallant

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Living Beings

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Joel Gallant (preview)

All Publications